Trials / Active Not Recruiting
Active Not RecruitingNCT04572854
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.
Conditions
- C3G
- IC-MPGN
- Renal Transplant
- Complement 3 Glomerulopathy
- Complement 3 Glomerulopathy (C3G)
- Dense Deposit Disease (DDD)
- Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis (MPGN)
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- C3 Glomerulopathy
- C3 Glomerulonephritis
- Complement 3 Glomerulonephritis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | Complement (C3) Inhibitor |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2023-02-27
- Completion
- 2026-01-01
- First posted
- 2020-10-01
- Last updated
- 2025-03-30
- Results posted
- 2025-02-07
Locations
25 sites across 11 countries: United States, Argentina, Australia, Austria, Brazil, France, Italy, Netherlands, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04572854. Inclusion in this directory is not an endorsement.